Every day, our industry works to develop new medicines that extend and improve the quality of life for patients. As the Baby Boom generation enters retirement age, one critical health care issue that we must address is how to keep our nation’s seniors healthy. It’s a topic that I come across regularly in my role at PhRMA.
According to new research by Milliman, a leading actuarial consulting firm, only about 3.3 percent of Part D enrollees filled a prescription for at least one specialty drug in 2011, a very small portion of total Part D enrollment.
We all know someone impacted by heart disease or stroke. Well that applies to the researchers working on medicines to combat these deadly diseases, as well. Not surprising when you consider that heart disease is the leading cause of death for both men and women, with someone dying from a heart disease related event every minute.
Last week, we introduced ‘Conversations,’ a new forum that provides experts, innovators, patients and other stakeholders an opportunity to share ideas through a live, ongoing dialogue about the future of health care.
We often discuss in the Catalyst the challenges and promise inherent in the drug discovery process and its impact on patients. And at times talk about how medicines, when used appropriately, can be a valuable part of the solution to controlling health care costs in the U.S.